Here is a Medpage article that broke July 23 describing the concern that Boehringer Ingelheim may have withheld data that supported dabigatran measurement in atrial fibrillation treatment. For the details, see Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. JACC 2014;63:321–8. For a provocative read, see Cohen D. Dabigatran: how the drug company withheld important analysis. BMJ 2014;349,g4670 (epub).
Jul 24 2014
Comments (0)Anticoagulant Therapy
No comments here.